Rolenium Elpenhaler

Description:
Rolenium Inhaler combines salmeterol and fluticasone propionate. When delivered via Elpenhaler, it offers long-acting bronchodilation and potent anti-inflammatory action to control asthma symptoms and reduce COPD flare-ups.

Directions:
1- Use the inhaler exactly as prescribed by your healthcare professional.

2- Inhale one dose (one blister/diskus) twice daily, approximately 12 hours apart.

3- Do not exceed the recommended dose.

4- Rinse mouth with water after inhalation to reduce the risk of oral thrush.

5- This medicine is for regular maintenance therapy, not for the relief of sudden asthma attacks.

6- Use a fast-acting inhaler (rescue inhaler) for acute symptoms if prescribed.

Active Ingredient(s):
Fluticasone Propionate, Fluticasone Propionate

FAQs:
Q: What is Rolenium Inhaler used for?
A: Rolenium Inhaler is used to control and prevent symptoms of asthma and to reduce flare-ups in patients with chronic obstructive pulmonary disease (COPD).

Q: How does Rolenium Inhaler work?
A: It contains two active ingredients: Salmeterol, which helps keep airways open for easier breathing, and Fluticasone Propionate, which reduces inflammation and swelling in the lungs. Together, they help control symptoms like wheezing, breathlessness, and coughing.

Q: How do I use the Rolenium Inhaler?
A: It is used with the Elpenhaler device. Place the capsule in the device, pierce it, and inhale deeply through the mouthpiece as directed by your doctor. Always follow your doctor’s instructions for proper use.

Q: Can Rolenium Inhaler be used during sudden asthma attacks?
A: No. It is a maintenance inhaler for long-term control and prevention. For sudden asthma symptoms, you should use a rescue inhaler prescribed by your doctor.

Q: How long does it take for Rolenium to work?
A: You may notice improvement in breathing within a few days, but full benefits are achieved with regular, long-term use.

For Consumers

For Healthcare Professionals

Part of

Stay informed about the future of healthcare

Visit our newsroom today to stay up to date.